ERA® is a diagnostic test patented by Igenomix in 2009

3 in every 10 implantation failure patients have a displaced window of implantation*

ERA analyzes 248 genes related to endometrial receptivity

Why choose Igenomix ERA test?

- ERA is backed by 21 publications 13 from Igenomix and 8 external publications.

- Randomized study in progress to assess its applicability in patients without any prior ART.

  (ClinicalTrials.gov Identifier: NCT01954758)

- Algorithms based on machine learning technologies.

- ERA allows clinicians to identify transition phases with 12 hours shifts.

How to perform ERA biopsy at HRT cycle

- Days with ESTRADIOL VALERATE
- Days with PROGESTERONE

Menstruation

VAGINAL ULTRASOUND
Triple layer > 6 mm
Endogenous P4 < 1 ng/ml

Biopsy
When is a second biopsy needed?

90% of cases don’t need a second biopsy. The second biopsy is only required under two circumstances:

- Patients with a “Pre-receptive” result, that need 2 days more on progesterone.
- Patients with a “Post-receptive” result.

In case of proliferative, non-informative, non-valid RNA or insufficient RNA result, the test should be repeated.